These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. Sartor O; Michels RM; Massard C; de Bono JS Oncologist; 2011; 16(11):1487-97. PubMed ID: 22048000 [TBL] [Abstract][Full Text] [Related]
23. Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge). Harzstark AL; Small EJ Expert Opin Biol Ther; 2007 Aug; 7(8):1275-80. PubMed ID: 17696825 [TBL] [Abstract][Full Text] [Related]
24. Clinical development of immunotherapy for prostate cancer. Noguchi M; Koga N; Igawa T; Itoh K Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142 [TBL] [Abstract][Full Text] [Related]
25. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer. Di Lorenzo G; Ferro M; Buonerba C BJU Int; 2012 Jul; 110(2 Pt 2):E99-104. PubMed ID: 22177289 [TBL] [Abstract][Full Text] [Related]
26. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Cheever MA; Higano CS Clin Cancer Res; 2011 Jun; 17(11):3520-6. PubMed ID: 21471425 [TBL] [Abstract][Full Text] [Related]
33. Prostate cancer immunotherapy: the role for sipuleucel-T and other immunologic approaches. Arlen PM Oncology (Williston Park); 2011 Mar; 25(3):261-2. PubMed ID: 21548469 [No Abstract] [Full Text] [Related]
34. The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature. Sonpavde G; Di Lorenzo G; Higano CS; Kantoff PW; Madan R; Shore ND Eur Urol; 2012 Apr; 61(4):639-47. PubMed ID: 22036643 [TBL] [Abstract][Full Text] [Related]
35. Complete Biochemical Response (Prostate Specific Antigen) to Sipuleucel-T in Metastatic Castrate-Resistant Prostate Cancer: A Case Report With Docetaxel Chemotherapy Administered Just Before Sipuleucel-T. McNamara M; Berry W Clin Genitourin Cancer; 2015 Oct; 13(5):e361-4. PubMed ID: 25735199 [No Abstract] [Full Text] [Related]
36. Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. Huber ML; Haynes L; Parker C; Iversen P J Natl Cancer Inst; 2012 Feb; 104(4):273-9. PubMed ID: 22232132 [TBL] [Abstract][Full Text] [Related]
37. Cancer immunotherapy: sipuleucel-T and beyond. Hammerstrom AE; Cauley DH; Atkinson BJ; Sharma P Pharmacotherapy; 2011 Aug; 31(8):813-28. PubMed ID: 21923608 [TBL] [Abstract][Full Text] [Related]
38. Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy. Mulders PF; De Santis M; Powles T; Fizazi K Cancer Immunol Immunother; 2015 Jun; 64(6):655-63. PubMed ID: 26025563 [TBL] [Abstract][Full Text] [Related]
39. Cabazitaxel: a novel drug for hormone-refractory prostate cancer. Malhotra M; Dhingra R; Sharma T; Deep A; Narasimhan B; Phogat P; Sharma PC Mini Rev Med Chem; 2013 May; 13(6):915-20. PubMed ID: 22950608 [TBL] [Abstract][Full Text] [Related]